Celltrion Reports Record Q2 Operating Profit of 430 Billion Won, Up 77% Year-on-Year

Celltrion achieved its highest-ever second-quarter performance this year.

On July 3, Celltrion announced that its consolidated operating profit for the second quarter reached 430 billion won, marking a 77.3% increase compared to the same period last year.

The company stated, "We exceeded our operating profit target of 400 billion won set earlier this year in our business and management plan for the second quarter." Revenue rose to 1.3 trillion won, a 35.2% increase from the previous year, while the operating profit margin improved from 25% to approximately 33%.

This strong performance is attributed to robust sales of existing key products and growth in high-margin new products. Sales of new products such as Remsima SC (marketed as Jimpendra in the U.S.), Uplima, and Stekima are increasing in major global markets, with new products now accounting for over 60% of total revenue.

In addition to its current growth, Celltrion is accelerating efforts to secure future growth drivers. The company is in the approval process for its biosimilar CT-P55, a treatment for autoimmune diseases, in South Korea and North America. It is also pursuing approvals for Herjuma SC in major countries and developing follow-up biosimilars for Keytruda and Darzalex.

Through these initiatives, Celltrion aims to expand its biosimilar portfolio to 30 products by 2030 and 41 by 2038.

In drug development, the company targets to secure a total of 20 new drug portfolios by next year. CT-P70 and CT-P71 have received Fast Track designation from the U.S. Food and Drug Administration (FDA).

Celltrion is also enhancing its production capacity to support its expanding product portfolio. In South Korea, it is working on expanding its 4th and 5th plants to a capacity of 180,000 liters, and it has decided to increase capacity by 75,000 liters at its Branchburg, New Jersey facility.

Meanwhile, Celltrion Group continues to invest in growth. Celltrion Pharmaceutical announced the establishment of a prefilled syringe (PFS) production hub in North Chungcheong Province, with a total investment of 2 trillion won, during a national report meeting on advanced industry development in the region.